Nancy Stagliano, CEO of Neuron23, discusses precision medicine in neuroscience drug discovery. Topics include genetic underpinnings of Parkinson's, studying neurodegeneration, transitioning from academia to biotech, challenges in drug discovery, focusing on Alzheimer's lead program, genetic links to neurological disorders, and future of targeted treatments.
Precision medicine in neuroscience targets genetic mutations for tailored therapy in neurodegenerative diseases.
Nancy Stagliano combines scientific expertise with business acumen to drive innovation in neurodegenerative treatments.
Neuron 23's focus on LARC2 mutations shows promise for selective therapy in Parkinson's patients.
Deep dives
Neuron 23: Precision Neuroscience for Neurodegenerative Diseases
Neuron 23, a biotech company, aims to translate genetics into targeted therapies for Parkinson's, Alzheimer's, and other neurodegenerative diseases. Using a precision neuroscience approach, they target LARC2 protein associated with Parkinson's. A blood-based companion diagnostic helps select patients with the LARC2 genetic signature most likely to benefit from the drug. Neuron 23's focus on genetics and biomarkers provides hope for more effective treatments in neurodegenerative diseases.
Nancy Stagliano's Journey from Science to Entrepreneurship
CEO Nancy Stagliano, with a background in neuroscience and industry experience, steered companies like Cytomics Therapeutics and True North Therapeutics towards successful acquisitions. Her focus on precision medicine with Neuron 23 aligns with her belief in translating research into patient benefits. Stagliano blends scientific depth with business acumen, driving innovation in neurodegenerative disease treatments.
LARC2 and Precision Medicine in Neurodegeneration
LARC2 kinase's role in cellular function and Parkinson's disease susceptibility drives Neuron 23's drug development. Genetics reveal specific mutations elevate Parkinson's risk, motivating precision therapy targeting hyperactive LARC2. The use of digital biomarkers in trials signals a shift towards objective, continuous monitoring in Parkinson's care. Neuron 23's focus on LARC2 mutations promises a tailored approach for a subset of Parkinson's patients.
Bio-marker Detection and Small Molecule Trials
Neuron 23's small molecule trials, like neu 411, for LARC2 inhibition show promising pharmacokinetic-pharmacodynamic relationships. Biomarkers in blood and CSF indicate effective target engagement and brain penetration potential. Preclinical data support neu 411's selectivity and tolerability, fueling optimism for phase 2 trials in Parkinson's patients. The strategic focus on precision and biomarker-driven therapies enhances the likelihood of successful outcomes.
Future Prospects for Precision Neuroscience
The integration of precision medicine in neuroscience holds potential for breakthroughs in treating complex neurodegenerative diseases. Emphasis on genetics, biomarkers, and digital monitoring heralds a future where tailored therapies based on molecular signatures revolutionize patient care. Neuron 23's commitment to precision neuroscience reflects a broader industry shift towards personalized, effective treatments for neurodegenerative disorders.